Anti-Aging Drug Discovery Targeting AKT

Aging is a complex biological process characterized by a gradual decline in physiological functions, which increases the risk of age-related diseases. The serine/threonine kinase AKT, also known as protein kinase B (PKB), is a key regulator of several cellular processes, including metabolism, proliferation, and apoptosis. It is activated by various growth factors and nutrients, leading to downstream signaling that promotes cell survival and growth. Research has shown that dysregulation of the AKT pathway is implicated in age-related diseases such as cancer, neurodegeneration, and metabolic disorders.

Fig. 1 Mechanism of AKT-induced senescence. (Astle MV, et al., 2012)

CD BioSciences provides anti-aging drug discovery services focusing particularly on the AKT signaling pathway due to its significant role in cell senescence and aging.

How Do We Target the AKT Signaling Pathway to Develop Anti-Aging Drugs?

At CD BioSciences, we employ a systematic approach to identify and validate the AKT signaling pathway as a potential therapeutic target for aging and age-related diseases.

• Molecular characterization of the AKT isoforms. AKT exists in three isoforms, AKT1, AKT2, and AKT3, each with distinct functions and tissue distributions. We help clients perform detailed molecular characterization to determine which isoforms are relevant to specific aging-related diseases.
• Bioinformatic analysis. We use bioinformatics tools to analyze large datasets and identify genes and pathways associated with aging that are modulated by AKT. Our approaches help clients understand the complex interactions within the aging network and the role of AKT as a nodal point.
• Target validation. Our team helps clients conduct experimental studies to validate the role of AKT in aging. To investigate the role of AKT signaling in cellular aging, we employ genetic manipulation to alter AKT activity in cultured cells. We then assess the impact on cell proliferation, apoptosis, and senescence.

Categories of Anti-Aging Drugs Targeting AKT We Can Develop

Small molecule inhibitors

We are actively helping clients develop small molecule inhibitors that can selectively block AKT activity. Our experts design these inhibitors to disrupt the signaling that leads to cellular aging and the onset of age-related diseases.

Peptide therapeutics

Peptides represent a promising approach to AKT inhibition. CD BioSciences helps clients investigate peptides that can bind to AKT or its activators, thereby inhibiting its activity and the aging-related processes it regulates.

What Experimental Models Do We Use in Anti-Aging Drug Discovery Targeting AKT?

• Cellular models. We provide human primary cells to study the physiological relevance of AKT modulation in aging. These cells offer a translational model to understand the effects of aging on cellular function and to assess the potential of AKT-targeting drugs to promote cellular rejuvenation. We also offer immortalized cell lines for high-throughput screening of potential drug candidates targeting the AKT pathway.
• Yeast models. Yeast, in particular, Saccharomyces cerevisiae, is a powerful model for studying fundamental biological processes associated with aging. By studying longevity and stress resistance in yeast strains with altered AKT signaling, we can identify potential therapeutic targets that may have conserved effects.
• Drosophila models. The fruit fly, Drosophila melanogaster, is a well-established model organism for aging research. We can manipulate AKT activity through pharmacological interventions, allowing our clients to observe effects on lifespan, fertility, and overall health. The short lifespan of Drosophila facilitates rapid screening of compounds and their effects on aging.
• Mouse models. We employ mouse models to help clients study the systemic effects of AKT modulation in aging. Our studies can reveal the role of AKT in age-related diseases, including cancer, metabolic disorders, and neurodegeneration.

CD BioSciences is committed to advancing anti-aging drug discovery with a focus on the AKT signaling pathway. Our comprehensive approach ensures the development of effective therapeutics to address the challenges of aging. If you are interested in our services, please feel free to contact us or make an online inquiry.

References

1. Cheng X, et al. Inhibitor GSK690693 extends Drosophila lifespan via reduce AKT signaling pathway. Mech Ageing Dev, 2022, 202: 111633.
2. Astle MV, et al. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene, 2012, 31 (15): 1949-62.